FBLG FibroBiologics (FBLG) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001958777
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
8
13F, latest reported quarter
What the filings say about FBLG
Activist stakes (13D), 180 days
1 filing
Largest: 7.5% of the class
FibroBiologics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for FibroBiologics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on May 27, 2025.
- +31.9% median (+31.9% mean) 90-day return after 2 previous buys.
- The trade is 49.0% of the 61,250 shares held after it.
- 3 other insiders bought within 30 days.
- 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Khoja Hamid bought about $11.4K of FBLG on Mar 4, 2026; 3 other insiders bought within 30 days and 8 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Mar 3, 2026.
- -85.6% median (-27.9% mean) 90-day return after 3 previous buys.
- The trade is 0.3% of the 5,958,147 shares held after it.
- 3 other insiders bought within 30 days.
- 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF EXECUTIVE OFFICER O'HEERON PETE bought about $6.0K of FBLG on Mar 4, 2026; 3 other insiders bought within 30 days and 8 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Mar 2, 2026.
- +0.9% median (+0.9% mean) 90-day return after 2 previous buys.
- The trade is 0.3% of the 5,942,275 shares held after it.
- 3 other insiders bought within 30 days.
- 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF EXECUTIVE OFFICER O'HEERON PETE bought about $7.5K of FBLG on Mar 3, 2026; 3 other insiders bought within 30 days and 8 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 12, 2024.
- The trade is 0.3% of the 5,924,075 shares held after it.
- 3 other insiders bought within 30 days.
- 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF EXECUTIVE OFFICER O'HEERON PETE bought about $6.1K of FBLG on Mar 2, 2026; 3 other insiders bought within 30 days and 8 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 70,000 shares held after it.
- 3 other insiders bought within 30 days.
- 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Davis Jason bought about $28.7K of FBLG on Mar 2, 2026; 3 other insiders bought within 30 days and 8 funds added in the latest 13F quarter.10 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
8 funds bought in last quarter
below 89% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
10.1% of the float short (float per yahoo 2026-10-26) · 3.8 days to cover · settled 2026-09-30
more than 63% of Pharma & Biotech
The situation: each line is one rule over one dataset
Hamid Khoja disclosed a 5%+ stake (7.5%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch FBLG
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-88.6%12M
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns FBLG: institutional holders (13F)
13F holdings, latest reported quarter
108,828 sh
$103.1K
51,794 sh
$49.1K
30,299 sh
$28.7K
27,769 sh
$26.3K
24,313 sh
$23.0K
Congress trades in FBLG
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Hamid Khoja
Activist 13D · 2026-09-17
7.5%
FBLG planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
FBLG mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$22.7K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$26.3K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$1.3K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$3.0K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$2.6K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 8 funds added last quarter. Each figure is a federal filing, dated the day it went public.
FBLG financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM FBLG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM FBLG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$14.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM FBLG
| FY Dec 2025 | -$16.7M |
| FY Dec 2024 | -$12.1M |
| FY Dec 2023 | -$6.9M |
| FY Dec 2022 | n/a |
| Jun 2026 | -$3.3M |
| Mar 2026 | -$4.4M |
| Dec 2025 | -$3.2M |
| Sep 2025 | -$4.0M |
| Jun 2025 | -$4.2M |
| Mar 2025 | -$5.3M |
| Dec 2024 | -$3.2M |
| Sep 2024 | -$2.6M |
At each fiscal year end
Single quarter
Debt to equity
0.01x
current debt only, 2022-10-31 (44 months older than the period end); equity 2026-06-30
Debt to equity FBLG
| FY Dec 2025 | 0.01x |
| FY Dec 2024 | 0.02x |
| FY Dec 2023 | 0.05x |
| FY Dec 2022 | n/a |
| Jun 2026 | 0.01x |
| Mar 2026 | 0.02x |
| Dec 2025 | 0.01x |
| Sep 2025 | 0.48x |
| Jun 2025 | 0.07x |
| Mar 2025 | 0.03x |
| Dec 2024 | 0.02x |
| Sep 2024 | 0.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-246.50x
TTM operating cash flow over current debt only, 2022-10-31 (44 months older than the period end)
Cash flow to debt FBLG
| FY Dec 2025 | -273.23x |
| FY Dec 2024 | -198.35x |
| FY Dec 2023 | -106.68x |
| FY Dec 2022 | n/a |
| Jun 2026 | -246.50x |
| Mar 2026 | -258.05x |
| Dec 2025 | -273.23x |
| Sep 2025 | -271.73x |
| Jun 2025 | -248.97x |
| Mar 2025 | -215.02x |
| Dec 2024 | -198.35x |
| Sep 2024 | -173.82x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-660.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity FBLG
| FY Dec 2025 | -419.4% |
| FY Dec 2024 | -559.7% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -660.1% |
| Mar 2026 | -754.7% |
| Dec 2025 | -419.4% |
| Sep 2025 | -1,293% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -559.7% |
| Sep 2024 | -267.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-166.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets FBLG
| FY Dec 2025 | -143.1% |
| FY Dec 2024 | -79.0% |
| FY Dec 2023 | -198.1% |
| FY Dec 2022 | n/a |
| Jun 2026 | -166.1% |
| Mar 2026 | -215.2% |
| Dec 2025 | -143.1% |
| Sep 2025 | -192.6% |
| Jun 2025 | -115.9% |
| Mar 2025 | -67.2% |
| Dec 2024 | -79.0% |
| Sep 2024 | -169.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital FBLG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-386.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed FBLG
| FY Dec 2025 | -287.6% |
| FY Dec 2024 | -432.2% |
| FY Dec 2023 | -4,571% |
| FY Dec 2022 | n/a |
| Jun 2026 | -386.4% |
| Mar 2026 | -469.3% |
| Dec 2025 | -287.6% |
| Sep 2025 | -611.3% |
| Jun 2025 | -1,867% |
| Mar 2025 | -4,712% |
| Dec 2024 | -432.2% |
| Sep 2024 | -329.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing FBLG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.8M
market value at close 2026-10-26 on 2026-07-31 shares, plus current debt only, 2022-10-31 (44 months older than the period end), minus cash 2026-06-30
Enterprise value FBLG
| FY Dec 2025 | $226.7M |
| FY Dec 2024 | $1.4B |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | $1.5M |
| Mar 2026 | $87.8M |
| Dec 2025 | $226.7M |
| Sep 2025 | $452.6M |
| Jun 2025 | $467.2M |
| Mar 2025 | $670.6M |
| Dec 2024 | $1.4B |
| Sep 2024 | $2.2B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-236.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield FBLG
| FY Dec 2025 | -7.2% |
| FY Dec 2024 | -0.9% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -299.6% |
| Mar 2026 | -17.6% |
| Dec 2025 | -7.2% |
| Sep 2025 | -3.6% |
| Jun 2025 | -3.2% |
| Mar 2025 | -1.9% |
| Dec 2024 | -0.9% |
| Sep 2024 | -0.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing FBLG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$16.6M | -$13.7M | -$8.9M | -$4.5M |
| Net income | -$18.6M | -$11.2M | -$16.5M | -$5.1M |
| EPS (diluted) | -0.42 | -0.34 | -0.68 | -0.18 |
| Operating cash flow | -$16.4M | -$11.9M | -$6.4M | -$4.1M |
| Cash | $4.9M | $14.0M | $9.2M | $2.3M |
SEC XBRL, fiscal years, as known on 2026-10-28
FBLG Stock Sonar score 4/7 axes
Find similar shapesCompareFBLG ranks highest on financial health (40th percentile) and risk and compliance (39th), and lowest on profitability (8th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
FBLG filings, in plain words
Read the full summary
1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 7.5% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
